ASP8273
Showing 1 - 7 of 7
Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations Trial in United States (naquotinib, midazolam)
Completed
- Non-Small-Cell Lung Cancer (NSCLC)
- Epidermal Growth Factor Receptor Mutations
-
Washington, District of Columbia
- +11 more
Jan 15, 2020
NSCLC Trial in Japan, Korea, Republic of, Taiwan (ASP8273)
Terminated
- Non-small Cell Lung Cancer
- ASP8273
-
Fukuoka, Japan
- +13 more
Oct 15, 2019
EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations Trial in Japan (ASP8273 Capsules, ASP8273 Capsules A)
Terminated
- EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations
- ASP8273 Capsules
- ASP8273 Capsules A
-
Fukuoka, Japan
- +10 more
Oct 22, 2018
NSCLC (NSCLC), Epidermal Growth Factor Receptor (EGFR) Mutations Trial in Beverly Hills, The Woodlands, Fairfax (naquotinib)
Terminated
- Non-small Cell Lung Cancer (NSCLC)
- Epidermal Growth Factor Receptor (EGFR) Mutations
-
Beverly Hills, California
- +2 more
Aug 30, 2018
NSCLC (NSCLC) Trial in Worldwide (naquotinib mesilate, Erlotinib, Gefitinib)
Terminated
- Non-small Cell Lung Cancer (NSCLC)
- naquotinib mesilate
- +2 more
-
Beverly Hills, California
- +166 more
Jan 24, 2019
Epidermal Growth Factor Receptor (EGFR) Mutations, Solid Tumors Trial (radio-labeled naquotinib, naquotinib)
Withdrawn
- Epidermal Growth Factor Receptor (EGFR) Mutations
- Solid Tumors
- radio-labeled naquotinib
- naquotinib
- (no location specified)
Jul 26, 2017
Subjects With NSCLC With an EGFR Activating Mutation Trial (ASP8273)
Withdrawn
- Subjects With NSCLC With an EGFR Activating Mutation
- ASP8273
- (no location specified)
Jul 7, 2017